© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Psyence Biomedical Ltd. (PBM) stock declined over -4.44%, trading at $2.50 on NASDAQ, down from the previous close of $2.62. The stock opened at $2.64, fluctuating between $2.47 and $2.64 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Feb 20, 2026 | 2.64 | 2.64 | 2.47 | 2.50 | 37.94K |
| Feb 19, 2026 | 2.65 | 2.65 | 2.42 | 2.62 | 29.41K |
| Feb 18, 2026 | 2.73 | 2.78 | 2.66 | 2.66 | 15.12K |
| Feb 17, 2026 | 3.07 | 3.09 | 2.72 | 2.79 | 45.34K |
| Feb 13, 2026 | 2.79 | 3.10 | 2.79 | 3.09 | 114.3K |
| Feb 12, 2026 | 2.87 | 3.01 | 2.73 | 2.81 | 82.07K |
| Feb 11, 2026 | 3.19 | 3.23 | 2.92 | 2.96 | 60.42K |
| Feb 10, 2026 | 3.14 | 3.21 | 3.00 | 3.18 | 45.15K |
| Feb 09, 2026 | 3.07 | 3.42 | 2.95 | 3.15 | 181.27K |
| Feb 06, 2026 | 2.85 | 3.27 | 2.75 | 3.13 | 98.92K |
| Feb 05, 2026 | 2.94 | 2.94 | 2.74 | 2.89 | 138.56K |
| Feb 04, 2026 | 3.07 | 3.25 | 2.54 | 3.24 | 195.67K |
| Feb 03, 2026 | 3.24 | 3.35 | 2.74 | 3.09 | 541.69K |
| Feb 02, 2026 | 3.96 | 12.64 | 3.65 | 3.80 | 5.04M |
| Jan 30, 2026 | 0.69 | 0.79 | 0.64 | 0.64 | 497.66K |
| Jan 29, 2026 | 0.69 | 0.83 | 0.67 | 0.72 | 274.7K |
| Jan 28, 2026 | 0.64 | 0.85 | 0.63 | 0.77 | 1.36M |
| Jan 27, 2026 | 0.65 | 0.66 | 0.63 | 0.63 | 147.21K |
| Jan 26, 2026 | 0.68 | 0.71 | 0.66 | 0.66 | 199.91K |
| Jan 23, 2026 | 0.75 | 0.75 | 0.69 | 0.73 | 215.45K |
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
| Employees | 12 |
| Beta | 0.32 |
| Sales or Revenue | N/A |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | N/A |
| Sector | Healthcare |
| Industry | Biotechnology |